| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Common Stock | 689,078 | $15,752,323 | $22.86 | 26 Jul 2021 | Direct |
| EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Common Stock | 14,880 | $340,157 | $22.86 | 26 Jul 2021 | By 401(k) |
| GENOCEA BIOSCIENCES, INC. | Director | Stock Option (Right to Buy) | 15,000 | 01 Jul 2021 | Direct | ||
| EXELIXIS, INC. | Pres, Prod Dev & Med Aff & CMO | Option (right to buy) | 0 | 26 Jul 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | 26 Jul 2021 | 2 | +$168,000 | 4 | Pres, Prod Dev & Med Aff & CMO | 28 Jul 2021, 20:06 |
| EXEL | EXELIXIS, INC. | 21 Jul 2021 | 2 | +$147,000 | 4 | Pres, Prod Dev & Med Aff & CMO | 23 Jul 2021, 19:47 |
| /report/000145761221000084-schwab-gisela-2021-07-01 | GENOCEA BIOSCIENCES, INC. | 01 Jul 2021 | 1 | $0 | 4 | Director | 02 Jul 2021, 11:59 |
| EXEL | EXELIXIS, INC. | 13 May 2021 | 3 | -$2,348,000 | 4 | Pres, Prod Dev & Med Aff & CMO | 14 May 2021, 20:35 |